NCT03609424 - PDR001 Plus Imatinib for Metastatic or Unresectable GIST | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

November 11, 2021

Study Completion Date

November 11, 2021

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

PDR001, Imatinib

"-Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested"

Trial Locations (1)

138-736

Asan Medical Center, Seoul